Summary
RGO Chart
Press Release: EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase 4 head-to-head respiratory study
EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase 4 head-to-head respiratory study
Dupixent® (dupilumab) Demonstrated Superiority Over Xolair® (Omalizumab) in Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) in Patients with Coexisting Asthma in First-ever Presented Phase 4 Head-to-Head Respiratory Trial
New late-breaking data at EAACI showed Dupixent outperformed Xolair across all primary and secondary efficacy endpoints of CRSwNP and in all asthma-related endpoints
23andMe Reaches Agreement for Sale of Business to TTAM Research Institute Following Final Round of Bidding in Court-Approved Sale Process
TTAM Commits to Comply with Company's Privacy Policy and All Applicable Laws TTAM Commits to Adopting Additional Consumer Protections and Privacy Safeguards to Enhance Protections for Customer Data and Privacy No Changes to 23andMe's Privacy Policy or Consumer Genome Services Transaction Subject to Court Approval SAN FRANCISCO, June 13, 2025 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (“23andMe” or the “Company”) (OTC: MEHCQ), a leading human genetics and biotechnology company, today announced that it has entered into a definitive agreement with TTAM Research Institute (“TTAM”), a nonprofit public benefit corporation based in California and led by 23andMe Co-Founder and former CEO Anne Wojcicki, for the sale of substantially all of the Company's assets, including the Personal Genome Service (PGS) and Research Services business lines and the Lemonaid Health business, for a purchase price of $305 million. The agreement with TTAM is the result of a final round of bidding that occurred earlier today between TTAM and Regeneron Pharmaceuticals, Inc. (“Regeneron”) (NASDAQ: REGN).
Regeneron Pharmaceuticals, Inc. Dividends
 RGO 11 Aug 2022 Paid | Other | €0 Per Share |
| RGO 15 Jul 2021 Paid | Other | €0 Per Share |
Regeneron Pharmaceuticals, Inc. Earnings
| 30 Jul 2025 (44 Days) Date | | - Cons. EPS | - EPS |
| 30 Apr 2025 Date | | - Cons. EPS | - EPS |
| 29 Apr 2025 Date | | - Cons. EPS | - EPS |
| 31 Jan 2025 Date | | - Cons. EPS | - EPS |
| 31 Oct 2024 Date | | - Cons. EPS | - EPS |
| RGO 11 Aug 2022 Paid | Other | €0 Per Share |
| RGO 15 Jul 2021 Paid | Other | €0 Per Share |
| 30 Jul 2025 (44 Days) Date | | - Cons. EPS | - EPS |
| 30 Apr 2025 Date | | - Cons. EPS | - EPS |
| 29 Apr 2025 Date | | - Cons. EPS | - EPS |
| 31 Jan 2025 Date | | - Cons. EPS | - EPS |
| 31 Oct 2024 Date | | - Cons. EPS | - EPS |
Regeneron Pharmaceuticals, Inc. (RGO) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
What is the earnings per share?
When is the next earnings date?
Has Regeneron Pharmaceuticals, Inc. ever had a stock split?
Regeneron Pharmaceuticals, Inc. Profile
| Biotechnology Industry | Healthcare Sector | Dr. Leonard S. Schleifer M.D., Ph.D. CEO | XFRA Exchange | US75886F1075 ISIN |
| US Country | 15,158 Employees | - Last Dividend | - Last Split | 2 Apr 1991 IPO Date |
Overview
Regeneron Pharmaceuticals, Inc. is a biotechnology firm that is renowned for its dedication to discovering, inventing, developing, manufacturing, and commercializing medicines to combat a variety of diseases globally. Since its inception in 1988, the company has been at the forefront of innovative treatments, striving to address the unmet medical needs of patients around the world. With its headquarters nested in Tarrytown, New York, Regeneron has made a significant impact in the pharmaceutical industry by delivering life-changing medicines to patients in need.
Products and Services
Regeneron Pharmaceuticals, Inc. offers a diverse portfolio of products aimed at treating a wide range of diseases, including but not limited to, eye diseases, allergies and inflammations, cardiovascular and metabolic conditions, infectious diseases, rare diseases, cancers, pain, and hematologic conditions.
- EYLEA Injection: Used for the treatment of wet age-related macular degeneration, diabetic macular edema, myopic choroidal neovascularization, diabetic retinopathy, neovascular glaucoma, and retinopathy of prematurity.
- Dupixent Injection: Offers relief for adults and children suffering from atopic dermatitis and asthma, targeting the underlying inflammation and immune system response.
- Libtayo Injection: Approved for the treatment of metastatic or locally advanced cutaneous squamous cell carcinoma, providing a much-needed option for patients with this serious skin cancer.
- Praluent Injection: Aimed at adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease, this medication works by reducing LDL cholesterol levels.
- REGEN-COV: For patients with COVID-19, offering a treatment option to help reduce the severity of the disease and potential hospitalization.
- Kevzara Solution: Designed for adults with rheumatoid arthritis, Kevzara works by interfering with the inflammatory pathway to reduce symptoms and slow disease progression.
- Inmazeb Injection: The first FDA-approved treatment for infection caused by Zaire ebolavirus, offering hope to patients facing this deadly disease.
- ARCALYST Injection: Treats cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and Muckle-Wells syndrome, by targeting the body’s inflammatory response.
- ZALTRAP Injection: Used in combination with chemotherapy for the treatment of metastatic colorectal cancer, aiming to slow the spread of the disease.
In addition to these products, Regeneron is continuously working on developing new treatments for a variety of diseases, demonstrating their commitment to innovation and improving patient health worldwide.
Contact Information
